A study of prevalence of HCV/HIV Co-Infection in a Tertiary Health Care Centre in Punjab
Keywords:
Coinfection, prevalence, hepatitisAbstract
Background: Coinfection with HIV and HCV is common since both infections share similar routes of transmission. Co-infection with hepatitis C virus and human immunodeficiency virus is common in certain populations. Among HCV (+) persons, 10% are also HIV (+), and among HIV (+) persons, 25% are also HCV (+). Many studies have shown that in intravenous drug users, coinfection prevalence can be as high as 90%-95%. There is increasing evidence supporting the concept that people infected with HIV have a much more rapid course of their hepatitis C infection. Treatment of co-infection is often challenging because highly active anti-retroviral therapy (HAART) is frequently hepatotoxic, especially in the presence of HCV. The purpose of this review is to describe the effects that HIV has on hepatitis C and the treatment options in this challenging population. This article shows the prevalence of Hepatitis C in HIV patients reported to Government Medical College/ Rajindra Hospital, Patiala. Methods: 4924 HIV positive patients registered under ART centre of GMC / Rajindra Hospital Patiala from 1 October, 2018 to 30th September, 201 st 9 were included in this study. HCV positive cases were detected by Elisa IgM and HCV RNA detection. Results: Out of 4924 HIV patients screened for HCV, 673(13.66%) patients were positive for HCV. Out of which 473(70.28%) were males and 200(29.7%) were females. Age distribution was done among these reactive patients and it was found that maximum number of HCV and HIV co-infected patients (383) were among the age group of 20 -40 years, which was 56.9% of total HCV and HIV co- reactive patients. Conclusion: HCV infection is common in HIV reactive patients. This coinfection is important due to common modes of infection in these two populations and prognostically due to early and rapid progression of liver disease in these patients.
Downloads
References
Provisional Population Totals: India. Census of India 2001. Series 1,Paper 1 of 2001.
UNAIDS/ WHO 2006 Report on the global AIDS epidemic.
WHO, Global surveillance and control of hepatitis C. Report of a WHO consultanion organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47
Goyal S, Sachdeva S, Singh G, Aggarwal R, Kaur S.A survey determining the different genotypes of Hepatitis C amongst subjects reporting to a tertiary care centre in Punjab. Int J Med Research Prof 2018 Jan; 4(1);283-85.
PlattL, Easterbrook P, Gower E, etal. Prevalence and burden of HCV co-infection in people living with HIV:aglobal systematic review and metaanalysis. Lancet Infect Dis 2016;16:797.
Mauss S, Rockstroh JK. HCV/ HIV-coinfection - is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemother 2005;56:615- 8.
Polis CB, Shah SN, Johnson KE, Gupta A. Impact of m ater nal HIV coinfection on the ver tical transmission of hepatitis Cvirus: ameta-analysis. ClinInfect Dis 2007; 44:1123.
KimAY, Chung RT. Coinfection with HIV-1 and HCV--a o n e -t w o p u n ch . Ga s t r o e n t e r o lo gy 2009;137:795.
Bräu N, Salvatore M, Ríos-Bedoya CF, etal. Slower fibrosis progression in HIV/ HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol2006;44:47.
Anderson KB, GuestJL, Rimland D.Hepatitis C virus coinfection increases mortality in HIVin fe ct e d p a t ie n t s in t h e h igh ly a ct ive antiretroviral therapy era: data from the HIV At l a n t a VA Co h o r t St u d y. Cl i n I n fe c t Dis2004;39:1507.
Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36:S93-
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
Bonacini M, Puoti M. Hepatitis C in patients with hum an im m unodeficiency vir us infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission and therapeutic issues. Arch Intern Med 2000;160:3365-73.
StraderDB,WrightT, Thomas DL, etal. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147.
Kim HN, Nance R, Van Rompaey S, etal. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J AcquirImmune Defic Syndr2016;72:437.
Newsum AM, Kooij KW, Boyd A, etal. Progressiono fliver fibrosis following acute hepatitis C virus infectionin HIV-positive MSM. AIDS 2019;33:833.
Augenbraun M, Goedert JJ, Thomas D, Feldman J, Seaberg EC, French AL, et al . Incident hepatitis C virus in women with human immunodeficiency virus infection. Clin Infect Dis 2003; 37:1357-64.
Salmon-Ceron D, Rosenthal E, Lewden C, etal. Emerging role of hepato cellular carcinoma among liver-related causes of deaths in HIVinfected patients: The Frenchnational Mortalité 2005 study. J Hepatol2009;50:736.
Merchante N, Merino E, López-Aldeguer J, etal. Increasing incidence of hepato cellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56:143.
Patel P, Hanson DL, Sullivan PS, etal. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. AnnInter n Med 2008;148:728.
Potter M, Odueyungbo A, Yang H, etal. Impact of h e p a t it is C vir a l r e p lica t ion on CD4 +Tlymphocyte progression in HIV-HCV coinfection before and after antiretro viral therapy. AIDS 2010; 24:1857.
Dong HV, Cortés YI, Shiau S, Yin MT. Osteoporosis a n d fr a ct u r e s in HIV/ h e p a t it is C vir u s coinfection: a system aticre view and metaanalysis. AIDS2014;28:2119.
O'Neill TJ, Rivera L, Struchkov V, etal. The effect of HIV-hepatitis C co-infection on bone mineral density and fracture: ameta-analysis. PLoSOne 2014;9:e101493.
